These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9339647)

  • 1. Effects of interferon alpha 2a on incidence of hepatocellular carcinoma in chronic active hepatitis without cirrhosis. Hepatitis Treatment Study Group.
    Sata M; Ide T; Akiyoshi F; Fukuizumi K; Noguchi S; Shirachi M; Sasaki M; Uchimura Y; Suzuki H; Tanikawa K
    Kurume Med J; 1997; 44(3):171-7. PubMed ID: 9339647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.
    Nishiguchi S; Kuroki T; Nakatani S; Morimoto H; Takeda T; Nakajima S; Shiomi S; Seki S; Kobayashi K; Otani S
    Lancet; 1995 Oct; 346(8982):1051-5. PubMed ID: 7564784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Varying incidence of cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis C responding differently to interferon therapy.
    Shindo M; Ken A; Okuno T
    Cancer; 1999 May; 85(9):1943-50. PubMed ID: 10223234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term evaluation of interferon therapy in hepatitis C virus-associated cirrhosis: does IFN prevent development of hepatocellular carcinoma?
    Tanaka K; Sata M; Uchimura Y; Suzuki H; Tanikawa K
    Oncol Rep; 1998; 5(1):205-8. PubMed ID: 9458323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the dose and duration of interferon-alpha therapy on the incidence of hepatocellular carcinoma in noncirrhotic patients with a nonsustained response to interferon for chronic hepatitis C.
    Toyoda H; Kumada T; Nakano S; Takeda I; Sugiyama K; Kiriyama S; Sone Y; Tanikawa M; Hisanaga Y; Hayashi K; Honda T
    Oncology; 2001; 61(2):134-42. PubMed ID: 11528252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
    Tanaka H; Tsukuma H; Kasahara A; Hayashi N; Yoshihara H; Masuzawa M; Kanda T; Kashiwagi T; Inoue A; Kato M; Oshima A; Kinoshita Y; Kamada T
    Int J Cancer; 2000 Sep; 87(5):741-9. PubMed ID: 10925370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis.
    Mazzella G; Accogli E; Sottili S; Festi D; Orsini M; Salzetta A; Novelli V; Cipolla A; Fabbri C; Pezzoli A; Roda E
    J Hepatol; 1996 Feb; 24(2):141-7. PubMed ID: 8907566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study.
    Izumi N; Asahina Y; Kurosaki M; Yamada G; Kawai T; Kajiwara E; Okamura Y; Takeuchi T; Yokosuka O; Kariyama K; Toyoda J; Inao M; Tanaka E; Moriwaki H; Adachi H; Katsushima S; Kudo M; Takaguchi K; Hiasa Y; Chayama K; Yatsuhashi H; Oketani M; Kumada H
    J Gastroenterol; 2013 Mar; 48(3):382-90. PubMed ID: 22875473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis.
    Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U
    Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of interferon-alpha for chronic hepatitis C.
    Moriyama M; Arakawa Y
    Expert Opin Pharmacother; 2006 Jun; 7(9):1163-79. PubMed ID: 16732703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group.
    Imai Y; Kawata S; Tamura S; Yabuuchi I; Noda S; Inada M; Maeda Y; Shirai Y; Fukuzaki T; Kaji I; Ishikawa H; Matsuda Y; Nishikawa M; Seki K; Matsuzawa Y
    Ann Intern Med; 1998 Jul; 129(2):94-9. PubMed ID: 9669992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of hepatocellular carcinoma after interferon therapy in patients with chronic hepatitis C.
    Onodera H; Ukai K; Suzuki M; Minami Y
    Tohoku J Exp Med; 1997 Feb; 181(2):275-83. PubMed ID: 9163844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment with interferon alfa-2b in patients with chronic hepatitis caused by hepatitis C virus: predictive factors for the response, relapse and early development to cirrhosis after treatment].
    Pérez Roldán F; De Diego A; Casado M; Matilla A; Bañares R; García-Durán F; Salcedo M; Cos E; Clemente G
    Rev Esp Enferm Dig; 1996 Sep; 88(9):609-15. PubMed ID: 8962775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival.
    Shiratori Y; Ito Y; Yokosuka O; Imazeki F; Nakata R; Tanaka N; Arakawa Y; Hashimoto E; Hirota K; Yoshida H; Ohashi Y; Omata M;
    Ann Intern Med; 2005 Jan; 142(2):105-14. PubMed ID: 15657158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The incidence and risk factors for the development of hepatocellular carcinoma after peginterferon plus ribavirin therapy for chronic hepatitis C.
    Dohmen K; Kawano A; Takahashi K; Shigematsu H; Tanaka H; Haruno M; Yanagita K; Ichiki Y; Mori T; Hayashida K; Shimoda S; Ishibashi H; Nomura H
    Hepatogastroenterology; 2013; 60(128):2034-8. PubMed ID: 24719946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment.
    Valla DC; Chevallier M; Marcellin P; Payen JL; Trepo C; Fonck M; Bourliere M; Boucher E; Miguet JP; Parlier D; Lemonnier C; Opolon P
    Hepatology; 1999 Jun; 29(6):1870-5. PubMed ID: 10347132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case report: development of hepatocellular carcinoma in a patient with chronic hepatitis C infection after a complete and sustained response to interferon-alpha.
    Hirashima N; Mizokami M; Orito E; Koide T; Itazu I; Kumada K; Sakakibara K; Kano H; Lau JY
    J Gastroenterol Hepatol; 1996 Oct; 11(10):955-8. PubMed ID: 8912134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-induced prolonged biochemical response reduces hepatocarcinogenesis in hepatitis C virus infection.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
    J Med Virol; 2007 Oct; 79(10):1485-90. PubMed ID: 17705189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.
    Moriyama M; Matsumura H; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Goto I; Tanaka N; Arakawa Y
    Liver Int; 2005 Feb; 25(1):85-90. PubMed ID: 15698403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.